Update: FDA Launches Rare Disease Framework Initiative

11:22 AM EDT, 10/15/2026 (MT Newswires) -- (Updates with details from the FDA's statement throughout) The US Food and Drug Administration said Wednesday that it will review its approach to drug development and approvals for rare diseases under a new Rare Disease Framework Initiative. "The goal is a regulatory framework where fit-for-purpose evidentiary expectations are the norm for all rare disease applications," the FDA said in its white paper. The agency said it will host a meeting on Oct. 28 to solicit feedback on the initiative from patients, businesses, and disease advocates. The initiative aims to develop a system that increases patient input and provides more regulatory clarity and consistency.